Collectively, these findings suggest that SEMA3C may be a putative driver of the cancer-promoting activities associated with FOXA1 variants, implying that the FOXA1 alterations commonly observed in clinical prostate cancer samples might mediate their oncogenic effects via SEMA3C. This evidence concerns the gene FOXA1 and prostate carcinoma.